Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference

Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress

Anavex Life Sciences to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results

Anavex Life Sciences to Participate at the BTIG Biotechnology Conference 2022

Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday, Aug. 9 2022

Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tues. May 10, 2022

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

Anavex Life Sciences Invited to Present at a Neuro & Ophthalmology Conference

Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference

Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study

Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum

Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71